Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
Balancing Safety and Access: Renal Denervation in Hypertension With Deepak L. Bhatt, MD, MPH, MBA
Deepak L. Bhatt, MD, MPH, MBA, of Mount Sinai Fuster Heart Hospital, spoke at the recent ASPC 2025 Congress on CVD Prevention to illustrate both the benefits and risks associated with renal denervation. Bhatt addresses the procedure in the context of lifestyle interventions and novel drug therapies.
Nomogram Aids Early Detection of Myasthenic Crisis Risk
Despite nurses often being the first health care workers many patients encounter, they frequently lack adequate tools to optimally evaluate their patients’ conditions, as in the case with myasthenia gravis and being able to predict patients at risk of myasthenic crisis.
TNX-102 SL Now Fourth FDA-Approved Treatment for Fibromyalgia
This approval brings the total to 4 of medications approved to treat fibromyalgia; in addition to cyclobenzaprine HCl sublingual tablets (TNX-102 SL; Tonmya; Tonix Pharmaceuticals), there are pregabalin (Lyrica; Viatris), duloxetine (Cymbalta; Eli Lilly), and milnacipran (Savella; AbbVie).
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Considerations for Patient Monitoring Following CAR T and Bispecific Administration: Amir Fathi, MD
Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients and their treatment team and key distinct toxicities that require vigilance.
Tricuspid Regurgitation Reliable Prognostic Indicator of PAH Severity
Despite knowledge of the benefits of right heart hemodynamic measures for evaluating patient prognosis in the setting of pulmonary arterial hypertension (PAH), gaps remain in a defined role for tricuspid regurgitation as it relates to echocardiographic phenotype.
Safety Should Always Be a Priority With CAR T for Multiple Myeloma: Surbhi Sidana, MD, MBBS
Cilta-cel’s mechanism of action allows it to penetrate challenging areas of multiple myeloma, providing deep and durable responses even in high-risk patients, explains Surbhi Sidana, MD, MBBS, Stanford University. Still, safety trade-offs should always be a consideration, she adds.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Long-Term Lebrikizumab Provides Sustained Skin Clearance in Atopic Dermatitis
In this subanalysis of data from the ADjoin trial of lebrikizumab, the interleukin-13 receptor inhibitor that is also a monoclonal antibody showed itself to be effective over the long term in patients with atopic dermatitis on maintenance therapy.
Sex-Based Cardiovascular Risks Linked to Cannabinoid Use: Rakendu Rajendran, MBBS
In this retrospective study, Rakendu Rajendran, MBBS, and colleagues found higher rates of myocardial infarction and major adverse cardiovascular events in males and increased stroke incidence in females, among cannabinoid users.
Recognizing and Addressing Primary Aldosteronism in Hypertension Management: Vivek Bhalla, MD
Vivek Bhalla, MD, Stanford, calls for greater awareness and implementation of existing screening guidelines to help identify patients who may benefit from more targeted, disease-specific interventions for hypertension in the setting of primary aldosteronism.
Exploring Pregnancy Outcomes in HFpEF and Cardiac Amyloidosis: Rayan Salih, MD
Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in Heart Failure With Preserved Ejection Fraction and Cardiac Amyloidosis.”
DETECT AS Trial Shows Notification System Closes Care Gaps: Varsha Tanguturi, MD
Varsha Tanguturi, MD, cardiologist and DETECT AS investigator, presented new data on how the findings she and her colleagues saw indicate almost universal increases in rates of aortic valve replacement in patients with severe aortic stenosis (AS), across both provider and patient groups.
TikTok's Role in Shaping Cholesterol Knowledge: Khush Kharidia, MD
Khush Kharidia, MD, a third-year internal medicine resident at UT Southwestern, presented the oral abstract, “Evaluating the Quality, Accuracy and Health Impact of Cholesterol-Related Content on TikTok: A Social Media Analysis,” at ASPC 2025 Congress on CVD Prevention.
Disparities in Pregnancy-Related Hypertension Among Hispanic Subgroups: Alexandra M. Trevino, MD
Alexandra M. Trevino, MD, of Northwestern Medicine presented the oral abstract, "Trends in New-Onset Hypertensive Disorders of Pregnancy Among US Adults by Place of Birth and Hispanic Ethnic Origin Group," on day 1 of the ASPC Congress on CVD Prevention.
Health System Fragmentation Undermines Timely Lung Cancer Testing: Julia Rotow, MD
In this first part of an interview with The American Journal of Managed Care®, Julia Rotow, MD, thoracic oncologist at Dana-Farber Cancer Institute, discusses the critical need to test for biomarkers to afford patients the chance to benefit from recent treatment advances.
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Addressing the Hidden Burden of Polycythemia Vera: Andrew Kuykendall, MD
Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.
Navigating Insurance Hurdles and Policy Shortfalls in Breast Cancer Care: Anasuya Gunturi, MD, PhD
At the recent regional Institute for Value-Based Medicine® event in Boston, Anasuya Gunturi, MD, PhD, Lowell General Hospital, was a panelist for the discussion, “Evolving Breast Cancer Care: Addressing Unmet Needs Across the Patient Journey.”